Results 131 to 140 of about 20,698 (251)

Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity [PDF]

Introduction: Obesity is a growing chronic condition worldwide with limited effective and safe treatment options. Semaglutide and liraglutide are two GLP-1a medications with encouraging outcomes for the treatment of obesity.
Bar, Orian
core  

The dual incretin agonist tirzepatide blunts nicotine‐induced behaviours and neurochemistry in male mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Nicotine dependence remains one of the leading causes of morbidity and mortality worldwide, with high relapse rates and post‐cessation weight gain representing persistent barriers to sustained abstinence. The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have ...
Christian E. Edvardsson, Thaynnam A. Emous, Sarah Witley, Mia Ericson, Louise Adermark, Elisabet Jerlhag   +5 more
wiley   +1 more source

Semaglutide-induced nonarteritic anterior ischemic optic neuropathy

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist widely used for type 2 diabetes and obesity management, has recently been associated with vision impairment, particularly nonarteritic anterior ischemic optic neuropathy (NAION).
Sumeet Lahane, Shruti Kochar, Rinal Pandit, Neeraj Israni, Rwituja Thomas, Dhaivat Shah   +5 more
core   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen   +4 more
wiley   +1 more source

Liver Organoids: From Disease Modelling to Regenerative Medicine

Cell Proliferation, EarlyView.
Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang, Xiaotian Qu, Jinhong Si, Junkang Meng, Ting Zhang, Shuliang Niu   +5 more
wiley   +1 more source

Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis. [PDF]

Clin Obes
Bhaduri G, Roy S, Kalia A, Gokalani R, Saboo B.   +4 more
europepmc   +1 more source

Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review

Diabetic Medicine, EarlyView.
Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo, Nikolaj Vang Nielsen, Julie Drotner Mouritsen, Michael Einar Røder, Jakob Linnet   +4 more
wiley   +1 more source

GLP-1R agonist semaglutide protects human forebrain organoids from cholesterol-induced neurotoxicity. [PDF]

Alzheimers Dement
Yu F, Xu J, Hou Y, Zheng H, Guo L, Khutsishvili D, Hai C, Xu W, Chen B, Wang Z, Ma S.   +10 more
europepmc   +1 more source

Semaglutide bij alcoholgebruiksstoornis: nieuwe RCT-data

Semaglutide verminderde het aantal consumpties per drinkdag, het aantal dagen met zwaar alcoholgebruik en de drang naar alcohol (craving) bij patiënten met een alcoholgebruiksstoornis.
David A. Gorelick
core   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source